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Abstract
Background: Alternative promoters usage is an important paradigm in transcriptional control of
mammalian gene expression. However, despite the growing interest in alternative promoters and
their role in genome diversification, very little is known about how and on what occasions those
promoters are differentially regulated. Runx1 transcription factor is a key regulator of early
hematopoiesis and a frequent target of chromosomal translocations in acute leukemias. Mice
deficient in Runx1 lack definitive hematopoiesis and die in mid-gestation. Expression of Runx1 is
regulated by two functionally distinct promoters designated P1 and P2. Differential usage of these
two promoters creates diversity in distribution and protein-coding potential of the mRNA
transcripts. While the alternative usage of P1 and P2 likely plays an important role in Runx1 biology,
very little is known about the function of the P1/P2 switch in mediating tissue and stage specific
expression of Runx1 during development.
Results: We employed mice bearing a hypomorphic Runx1 allele, with a largely diminished P2
activity, to investigate the biological role of alternative P1/P2 usage. Mice homozygous for the
hypomorphic allele developed to term, but died within a few days after birth. During
embryogenesis the P1/P2 activity is spatially and temporally modulated. P2 activity is required in
early hematopoiesis and when attenuated, development of liver hematopoietic progenitor cells
(HPC) was impaired. Early thymus development and thymopoiesis were also abrogated as reflected
by thymic hypocellularity and loss of corticomedullary demarcation. Differentiation of CD4/CD8
thymocytes was impaired and their apoptosis was enhanced due to altered expression of T-cell
receptors.
Conclusion: The data delineate the activity of P1 and P2 in embryogenesis and describe previously
unknown functions of Runx1. The findings show unequivocally that the role of P1/P2 during
development is non redundant and underscore the significance of alternative promoter usage in
Runx1 biology.
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Background
The mammalian RUNX1 belongs to the runt domain fam-
ily of transcription factors. The members of this gene fam-
ily, RUNX1, RUNX2 and RUNX3  are key regulators of
lineage-specific gene expression in major developmental
pathways [1-3]. The three RUNX proteins recognize the
same DNA-motif and regulate their target genes through
interaction with a common group of transcriptional co-
activators or co-repressors [4-7]. Interestingly, however,
the functional overlaps are minor and each RUNX protein
has a distinct subset of biological functions. Accordingly,
each of the corresponding RUNX knockout (KO) mice
displays a unique subset of phenotypic abnormalities [3].
This lack of functional redundancy results from a tightly
regulated spatio/temporal expression mediated by an
intricate transcriptional control [3,8]. For example, both
Runx1 and Runx3 genes are expressed in developing dorsal
root ganglia, but in different classes of sensory neurons [9-
12] and both are expressed in mature T cells, but at differ-
ent stages during T cell development [13-15].
In the mouse embryo, expression of Runx1 is first detected
in definitive hematopoietic stem cells (HSC) and in
endothelial cells at HSC emergence sites [16-18]. These
occurrences correlate well with the earlier findings that
homozygous disruption of Runx1 results in a complete
absence of fetal liver hematopoiesis [19,20]. Postnatally,
Runx1 is highly expressed in several hematopoietic line-
ages including myeloid, B- and T-lymphoid cells [2,21,22]
and is required for megakaryocytic maturation [23]. In
contrast to the critical role of Runx1 during embryogene-
sis, it is less essential for adult hematopoiesis [2], albeit
conditional inactivation is associated with a number of
hematopoietic abnormalities including myeloprolifera-
tion [24].
Runx1 is also expressed in a number of other tissues at
specific time windows during embryogenesis [2,3]. How-
ever, due to the early (E12.5) lethality of homozygous
null Runx1 mice [16,19,20], relatively little is known
about the function of Runx1 in these tissues. In develop-
ing thymus Runx1 is more abundantly expressed in the
cortex [9,14] during early stages of thymopoiesis [13].
Transgenic mice that express a dominant-negative form of
Runx1 display defects in maturation of single positive (SP)
CD4 and SP CD8 thymocytes [25]. Additionally, naive T
cells from these mice exhibited increased production of
IL4, lack of GATA3 expression and enhanced Th2 differen-
tiation of CD4+ helper-T cells [26]. Selective inactivation
of Runx1 in T-cell progenitors demonstrated that Runx1
acts in double negative (DN) thymocytes to repress CD4
expression and to up-regulate CD8 as cells differentiate
into the double positive (DP) thymocytes [13,27]. ES cells
bearing a mutant Runx1 lacking the C-terminal repression
sub-domain, failed to adequately contribute to the thy-
mus in chimera mice [28]. In the knock-in model of this
mutant, the overall number of thymocytes was signifi-
cantly reduced and the thymus contained a higher propor-
tion of SP CD4 cells [28].
We have previously shown that transcription of Runx1 is
regulated by two distantly located promoter regions desig-
nated P1 and P2 for the distal and proximal, respectively
[29]. The P2 is nested within a particularly large and evo-
lutionary conserved CpG island [3,9], while no such CpG
rich region is found in P1. The two promoters are regu-
lated in a cell type-specific manner and respond to
mitogenic stimulation [30,31]. The P1- and P2-derived
primary transcripts are processed into a diverse repertoire
of alternatively spliced mRNAs that are differentially
expressed in various cell types and at different develop-
mental stages [3]. The P1 and P2 mRNAs differ at their 5'-
coding regions [9,31], and the resulting protein isoforms
differ in their biological functions [1,32-34]. Similarly, a
number of P2-derived splice-variants bear shorter reading
frames that lack the transcriptional activation domain and
can act in a dominant negative manner [31]. Forced
expression of such isoforms results in transcriptional
repression of Runx1 target genes [35-37], and in blocking
of myeloid differentiation [36]. Hence, differential usage
of P1 versus P2 has a profound effect on the repertoire and
nature of Runx1 isoforms in the cell, which likely impacts
on the regulation of Runx1 target genes [8]. Significantly,
disruption of P1 by the 12;21 chromosomal translocation
results in the most common subtype of childhood acute
lymphoblastic leukemia [38].
P1- and P2-transcripts also differ in the structure and func-
tion of their 5' untranslated region (5'UTR). The P1-5'UTR
is relatively short and mediates cap-dependent transla-
tion, whereas the P2-5'UTR is particularly long, contains
an internal ribosome entry site (IRES) and mediates cap-
independent translation [3,30]. These structurally and
functionally different 5'UTRs could have a profound effect
on translation efficiency of Runx1 mRNAs. Indeed, in cell
lines where P2 transcription predominated, P2-5' IRES-
dependent translation was more efficient than P1-5' cap-
dependent translation [3,30]. IRES-dependent translation
is particularly important during development, in times
when cap-dependent translation in proliferating or differ-
entiating cells is down-regulated [39]. While it is clear that
the regulation of Runx1 expression by alternative P1/P2
usage is a potentially key paradigm in the in vivo regula-
tion of Runx1, very little is known about the role of the
P1/P2 switch in mediating tissue and stage specific expres-
sion of Runx1 during development.
To investigate the biological function of the P1/P2 switch
during embryogenesis, we generated mice bearing a hypo-
morphic Runx1 allele by inserting a neomycin (neo) geneBMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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into the P2 region (P2neo). Mice homozygous for the P2neo
allele (P2neo/neo) displayed a markedly attenuated P2
activity. Nevertheless, these mutant mice developed to
term, but newborns died within a few days after birth. We
show that the P1/P2 switch is developmentally regulated
and that the two promoters are alternatively used during
embryogenesis. P2 mediated transcription is required dur-
ing early thymopoiesis for the proper development of the
thymus and for differentiation of DN and DP CD4/CD8 T
cells. Attenuation of P2 activity results in impaired devel-
opment of fetal liver hematopoietic precursors and in
enhanced apoptosis of thymocytes due to altered expres-
sion of T-cell receptors (TCRs). The data describe previ-
ously unknown functions of Runx1, delineate the activity
of P1 and P2 in embryogenesis, show unequivocally that
their function during development is non redundant and
underscore the significance of the two promoters in Runx1
biology.
Results
Generation of Runx1 P2neo/neo mice and phenotypic 
analysis of mutant newborns
Null mutation in Runx1  results in embryonal lethality
[19,20]. As P2 activity starts early in embryogenesis
(Levanon D. and Groner Y. unpublished), we envisaged a
scenario in which germline inactivation of P2 will also
result in embryonal death. To avoid this occurrence we
explored means to selectively attenuate the activity of
Runx1  P2. We have previously demonstrated that the
genomic region upstream the transcription start sites of
RUNX1 P2 was important for regulated transcription of
RUNX1  in various cell lines [29,30]. We thus assessed
whether insertion of a neo cassette into this region affects
P2 activity in transfected cells (See additional file 1: Fig.
1A and 1B for constructs, results and methods). Transfec-
tion experiments indicated that insertion of a neo cassette
into the P2 region specifically attenuated P2-mediated
transcription in several cell lines and encouraged us to uti-
lize this approach for evaluating the biological activity of
Runx1 P2 in vivo.
Runx1 P2 was targeted in ES cells using a construct in
which the neo cassette was placed at the same site as in the
P2neo-Ren construct (Additional file 1), but in a transcrip-
tional orientation opposite to that of Runx1, and was
flanked by lox P sites (Additional file 2A). Homologous
recombination yielded ES clones (Additional file 2B),
which were used to generate several Runx1P2neo/+ chimeric
males that passed on the Runx1 mutation through the
germ line. Mating F2 heterozygotes with 129/Sv, ICR or
MF1 mice generated Runx1P2neo/neo mice with an inbred or
a mixed background. Heterozygous Runx1P2neo/+ (P2neo/+)
mice appeared phenotypically indistinguishable from
their WT littermates. However, homozygous Runx1P2neo/
neo (P2neo/neo) neonates were reduced in size, gained little
weight and most of them died 2 to 3 days post natally
(Additional file 2D).
To further characterize the phenotype/genotype relation-
ships of the mutant mice, heterozygotes P2neo/+ mice were
mated with two different strains of transgenic mice
expressing Cre driven by either PGK or EIIa promoters
[40,41] (Additional file 2B). The resulting heterozygotes
bearing the remaining loxP sequence within the P2-XbaI
site were mated and offspring homozygous to P2-loxP
were obtained at the expected Mendelian proportion
(25%). Significantly, Runx1P2loxP/loxP  (P2loxP/loxP) mice
were indistinguishable form WT littermates indicating
that the early lethality phenotype of P2neo/neo newborns
was due to the presence of the neo  cassette in the P2
region.
Attenuated Runx1 expression in P2neo/neo mice
The above-described phenotypic manifestation of the
P2neo/neo allele posed a question as to how the expression
level of Runx1 was affected. To address this issue, Runx1
expression in various tissues was examined using RT-PCR,
immunohistochemistry (IHC) and RNA in situ hybridiza-
tion (RISH) (Fig. 1). In tissues of P2neo/neo mice, such as
kidney and tongue, where Runx1 expression is normally
mediated by both P1 and P2, only P1-transcripts were
detected (Fig. 1A). In contrast, no Runx1 expression was
detected by either RT-PCR or IHC in developing gastric
epithelium where only P2 is normally active (Figs. 1A and
1B). P2neo is therefore a hypomorphic allele of Runx1 in
which P2 activity is largely diminished. Interestingly,
however, no developmental abnormalities were detected
by macroscopic and histological examination of kidney,
stomach and tongue of mutant embryos or newborns. The
most obvious and consistent macroscopic abnormality
was a profound reduction in size of the thymus of new-
born P2neo/neo mice as compared to WT (Fig. 1C).
Western blot analysis, RISH using a P2 specific probe and
RT-PCR showed that during early thymogenesis (embryo-
nal day (E) 14.5–16.5) transcription of Runx1 in WT thy-
mus was predominately mediated by P2 (Fig. 1D), and
that at this stage almost no Runx1 was detected in P2neo/
neo thymus (Figs. 1E and 1F). The P1 activity in WT thymus
was switched-on between E15.5–E17.5 and persisted
thereafter, whereas the activity of P2, which predominated
during embryogenesis, gradually decreased after birth
(Fig. 1D). Importantly, once switched-on the P1 activity
was apparently unaffected in P2neo/neo mice, as evidenced
by northern blot analysis of Runx1 mRNAs in newborns
(Fig. 1G). Together, the complementary results of Runx1
expression studies and morphological analyses showed
that expression of Runx1 in P2neo/neo mice was compro-
mised both temporally and spatially, resulting in adverse
effect on thymus development.BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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Attenuated Runx1 P2 expression in P2neo/neo embryos impaired thymus development Figure 1
Attenuated Runx1 P2 expression in P2neo/neo embryos impaired thymus development. (A) RT-PCR analysis of RNA 
from kidney and stomach of E16.5 WT and P2neo/neo embryos, and from tongue of P1.5 WT and P2neo/neo neonates. P2-medi-
ated transcription in P2neo/neo tissues diminished, whereas P1-mediated transcription was largely unaffected. (B) IHC analysis of 
glandular stomach of E16.5 WT (left) and P2neo/neo (right) embryos. Runx1 expression is detected in epithelial cells of WT 
embryo, but missing in P2neo/neo littermate (10× magnification). (C) Reduced size of thymic lobes in P1.5 P2neo/neo mice (right) as 
compared to WT littermate (left). (D) RT-PCR analysis of Runx1 P1- and P2-mediated transcription in thymus of WT embryos, 
neonates and young mice. (E) Analysis of Runx1 expression by In-situ hybridization of E15.5 WT (left) and P2neo/neo (right) 
thymic sections, using the P2-5'UTR probe. P2-derived transcripts are clearly visible in the cortex of E16.5 WT, but not of 
P2neo/neo (10× magnification). (co) = cortex; (me) = medulla. (F) Western blot analysis of proteins extracted from thymus of 
E15.5–E17.5 WT and P2neo/neo embryos. Runx1 proteins were not detected in E15.5 P2neo/neo thymus, but gradually accumu-
lated in E16.5 and E17.5 thymi. (G) Northern blot analysis of RNA from thymi of WT and P2neo/neo newborn mice. Whereas 
P2-mediated transcription (the 4 Kb and 8 Kb transcripts) [30, 31], in P2neo/neo thymocytes was markedly attenuated, P1-medi-
ated transcription (the 2 Kb and 6 Kb transcripts) was apparently unaffected. (H) Reduced thymus cellularity in P2neo/neo 
embryos and neonates. Five mice of each genotype were analyzed. The difference between the number of thymocytes from 
WT and P2neo/neo thymus was significant at P < 0.0001 (*) and P < 0.05 (#) by Student's t test.BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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Impaired thymus development in Runx1 P2neo/neo mice
Thymus development in mouse embryo begins at E9.5
ensued by immigration of lymphocyte precursors into the
thymic rudiment at E14.5. Development proceeds
through stage specific interactions between thymocytes
and thymic epithelium that are essential for the formation
of thymic architecture [42]. Runx1 is highly expressed in
developing thymocytes, but not in thymic epithelium
[9,13,14].
Macroscopic examinations revealed that thymi of P2neo/
neo neonates were about one-third of the normal size
(Figs. 2I and 2K). This diminished size was caused by a
profound reduction in the number of thymocytes during
mutant thymus development (Fig. 1H). Histological
examinations revealed no gross morphological differ-
ences between P2neo/neo and WT at E14.5 and E15.5 (Figs.
2A and 2C), except for scattered cysts in P2neo/neo thymi
(Fig. 2C). These cysts are thought to result from acceler-
ated epithelial turnover within centers of epithelial
islands [43]. At E16.5 however, extensive histological dif-
ferences between WT and P2neo/neo emerged (Fig. 2E). WT
thymus had a clear demarcation of cortex and medulla.
WT cortex was densely cellular with small hyperchromatic
thymocytes, while the medulla was paler, contained a
lower number of thymocytes admixed with macrophages,
epithelial cells, and antigen presenting cells (Fig. 2E).
Mutant thymus, on the other hand, was much smaller,
hypocellular, had a scalloped capsular surface and con-
sisted predominantly of epithelial cells, with no evidence
of an organized cortex and medulla. At E17.5 the histolog-
ical defects were even more pronounced; the P2neo/neo thy-
mus still lacked corticomedullary organization and
contained occasional cysts (Fig. 2G).
IHC using anti Runx1 antibodies revealed a lower number
of Runx1 positive cells in E14.5 and E15.5 P2neo/neo thymi
compared to WT (Figs. 2B and 2D). Runx1 is mostly
expressed in DN CD4-/CD8- immature thymocytes, where
it regulates CD4 expression [13,25,28]. IHC of E15.5–
E16.5 WT thymus revealed that these Runx1 positive
immature thymocytes were predominantly in the cortex
and less in the medulla (Figs. 2D and 2F), as also shown
by the RNA in-situ hybridization data (Fig. 1E). In P2neo/
neo thymus on the other hand, the fewer Runx1 positive
cells were scattered randomly within the organ (Fig. 2D).
At E17.5 most of Runx1 expressing DN CD4-/CD8- thy-
mocytes were found in the sub-cortical band (SCB),
whereas the cortical, DP CD4+/CD8+ thymocytes did not
express Runx1 (Fig. 2H). In E17.5 P2neo/neo thymus, many
Runx1 positive cells were still in the cortex and only after
birth, when the mutant thymus gradually gained WT mor-
phology, were Runx1 expressing hyperchromatic cells
seen in the SCB (Figs. 2J and 2L). But even then, the over-
all size of mutant thymus remained much smaller com-
pared to WT (Figs. 2I and 2K). The data indicate that
normal embryonal thymopoiesis depends on a proper P2-
mediated transcription of Runx1 which when attenuated
during the E14.5–E16.5 time period results in impaired
thymus development.
Increased apoptosis in embryonal P2neo/neo thymocytes
To directly assess whether the thymic hypocellularity of
P2neo/neo embryos was a consequence of enhanced cell
death, the proportion of apoptotic thymocytes was deter-
mined by flow cytometry. At E14.5 a much higher propor-
tion of P2neo/neo thymocytes (63% ± 5) compared to WT
(28% ± 8) bound annexin V, indicating increased apopto-
sis among P2neo/neo thymocytes (Fig. 3A). Additionally,
increased proportion of necrotic cells positive to both
annexin V and propidium iodid (PI), was observed in
P2neo/neo thymus (15% ± 3 P2neo/neo; 10% ± 2 WT, Fig. 3A).
The enhanced cell death of E14.5 P2neo/neo thymocytes led
to a three-fold reduction in the proportion of viable thy-
mocytes in mutant thymus (WT 61.0% ± 5; P2neo/neo
21.9% ± 3). At E16.5–17.5 the P1 promoter is switched on
(Figs. 1D and 1F), expression of Runx1 in P2neo/neo thymo-
cytes increased (Figs. 2F and 2H) and recovery of thy-
mopoiesis commenced. The end result was an increased
proportion of viable P2neo/neo thymocytes at E17.5 almost
to WT level (Fig. 3A). The enhanced apoptosis in P2neo/neo
E14.5 and E15.5 thymus was also demonstrated by in situ
TUNEL labeling and IHC of activated caspase-3 (not
shown). The proportion of non-viable thymocytes at var-
ious stages of thymus development is shown in Fig. 3B. At
early stages, apoptosis was significantly higher in P2neo/neo
fetuses compared to WT, but gradually declined concom-
itant with the increase in P1-mediated expression of
Runx1.
We next asked whether the proliferative capacity of P2neo/
neo thymocytes was also affected. E15.5 thymocytes were
isolated, analyzed by FACS and similar numbers of viable
cells cultured in-vitro under proliferation stimulating con-
ditions (Fig. 3C). Purified P2neo/neo and WT thymocytes
displayed a similar thymidine incorporation rate, indicat-
ing that the ability of thymocytes to proliferate was hardly
affected by the attenuated expression of Runx1 during
early thymopoiesis. This conclusion was supported by
immunostaining of thymocytes with the cell prolifera-
tion-associated antigen Ki-67. In E15.5 P2neo/neo thymus
the number of Ki-67 positive cells was lower than in WT
(Fig. 3C), reflecting the hypocellularity of mutant thymus
(Fig. 2D). Nevertheless, significant numbers of P2neo/neo
thymocytes did express Ki-67, indicating normal progres-
sion through the cell cycle. Together, these results show
that P2neo/neo thymocytes possess proliferation and cell
cycle progression capabilities similar to WT, but attenuat-
ing Runx1 expression during early developmental stagesBMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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rendered thymocytes more susceptible to apoptosis, lead-
ing to thymic hypocellularity.
To address whether the increased apoptosis of P2neo/neo
thymocytes was due to loss of a cell-autonomous function
of Runx1, we examined the capacity of P2neo/neo thymo-
cytes to populate fetal thymic organ culture (FTOC).
E14.5 WT thymic lobes were reconstituted, at a saturating
cell number, with either WT or P2neo/neo E15.5 fetal liver
(FL) cells that contain hematopoietic progenitor cells
(HPC). At FTOC day 14 and 16, cells were extracted out of
the lobes and analyzed by FACS for Annexin V binding.
P2neo/neo HPC gave rise to a significantly lower number of
FTOC cells compared to WT and most P2neo/neo derived
cells were Annexin Vhigh (Fig. 3D). These data further dem-
onstrated the intrinsic requirement for P2-mediated
expression of Runx1 during early embryonal thymopoie-
sis.
The enhanced apoptosis of P2neo/neo thymocytes is 
associated with increased expression of TCRβ/TCRγδ
The above results raised the question of how does attenu-
ated expression of Runx1 cause the increased apoptosis of
P2neo/neo thymocytes. The majority of immature thymo-
cytes with a non-productive rearrangement of TCRβ gene
die through Fas/Fas ligand-mediated apoptosis [44]. Only
Histological and IHC analysis of thymus development in WT and P2neo/neo mice Figure 2
Histological and IHC analysis of thymus development in WT and P2neo/neo mice. (A, C, E, G, I, K) Transverse sec-
tions of WT (left panels) and P2neo/neo (right panels) thymic lobes stained with hematoxylin and eosin (HE). co = cortex, me = 
medulla, scb = sub-cortical band, cy = cyst. (B, D, F, H, J, L) Immunostaining of Runx1 in sections of WT (left panels) and P2neo/
neo (right panels) thymic lobes. Runx1 is detected in thymocytes, but not in thymic epithelium. A reduced number of Runx1 
expressing thymocytes (that are abnormally distributed) is seen in P2neo/neo thymic lobes.BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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P2neo/neo thymocytes display enhanced apoptosis, but have normal cell proliferation capacity Figure 3
P2neo/neo thymocytes display enhanced apoptosis, but have normal cell proliferation capacity. (A) FACS analysis of 
E14.5 and E17.5 WT (left panels) and P2neo/neo (right panels) thymocytes stained with Annexin V and PI. FACS dot plots and 
percentages of cells in each quadrant are indicated. Note the >2 fold increase in the proportion of apoptotic cells (Annexin V+/
PI-) and of necrotic cells (Annexin V+/PI+) in P2neo/neo thymi. (B) P2neo/neo thymocytes display enhanced apoptosis throughout 
embryonic thymopoiesis. Proportion of non-viable (apoptotic+necrotic) WT and P2neo/neo cells gradually decreased during 
embryonic development. Nevertheless, at any given time point, P2neo/neo thymui contained a higher proportion of non-viable 
cells compared to WT littermates. After birth the proportion of non-viable thymocytes in P2neo/neo became similar to WT. At 
least five mice of each genotype were analyzed. The differences between WT and P2neo/neo apoptotic thymocytes were signifi-
cant at P < 0.001 (*) and P < 0.01 (#) by Student's t test. (C) P2neo/neo thymocytes retain normal proliferation capacity. Follow-
ing FACS analysis an equal number (1 × 104) of E15.5 WT or P2neo/neo Annexin V negative thymocytes were incubated with 
TPA (20 ng/ml) and ConA (5 μg/ml) for 48 h. 3H-thymidine was present during the last 18 h of incubation. Differences between 
WT and P2neo/neo were statistically insignificant by Student's t test. Proliferation capability of thymocytes was further examined 
by immunostaining of E15.5 thymic lobes for the proliferation-associated antigen recognized by Ki-67 antibodies (Right panels). 
(D) Enhanced embryonal apoptosis is a cell-autonomous property of P2neo/neo thymocytes. WT or P2neo/neo E15.5 FL HPC were 
differentiated under saturating conditions in E14.5 WT FTOC for 14 or 16 days. We predetermined that ~100 FL cells (either 
WT or P2neo/neo) per lobe were sufficient to populate all available thymic lobes and therefore used 1000 FL cells per lobe. Thy-
mocytes accumulation in FTOC populated with P2neo/neo FL HPC is reduced compared to WT (left panel WT-black; P2neo/neo-
white). Proportion of apoptotic thymocytes (Annexin V+) derived from FTOC populated with P2neo/neo FL cells (red) was con-
siderably higher compared to WT (light blue) (right panel).BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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a small subset of immature thymocytes with productive
TCRβ or γδ rearrangement are selected for further matura-
tion associated with rapid proliferation [45-48]. Interest-
ingly, the percentage of TCRβ/TCRγδ expressing
thymocytes was significantly higher in E14.5 to E17.5
P2neo/neo fetuses compared to WT (Figs. 4A and 4B), as was
the mean-fluorescence-intensity (MFI) level of TCRβ+ thy-
mocytes (Fig. 4B). These data indicate an enhanced TCRβ/
γδ expression on P2neo/neo thymocytes compared to WT
during the early stages of embryonal thymopoiesis.
Runx1 acts in transfected cells as a negative regulator of
TCRβ transcription [4]. It is thus possible that the dimin-
ished Runx1 expression between E14.5 to E16.5 caused
de-repression of TCR transcription in P2neo/neo thymo-
cytes, leading to the increased level of TCRβ/γδ. Support-
ing this assumption are data demonstrating that
upregulation of TCRβ/γδ in P2neo/neo thymocytes occurred
at the transcriptional level (Fig. 4C), and that down regu-
lation to WT levels occurred at E18.5 (Fig. 4A and 4B),
upon turning-on of P1 (Fig. 1).
We next addressed whether increased expression of TCRβ/
γδ in P2neo/neo  thymocytes was associated with the
increased susceptibility to apoptosis of the mutant cells.
Annexin V staining was monitored in fractionated TCRβ+
or TCRγδ+ thymocytes (Figure 4D). In E15.5 and E16.5
embryos 50–65% of WT and 80–90% of P2neo/neo TCRβ+
thymocytes were apoptotic as were ~95% of both WT and
P2neo/neo TCRγδ+ thymocytes (Figs. 4D and 4E). Addition-
ally, at these developmental stages a significantly higher
proportion of P2neo/neo thymocytes express the TCRs (Figs.
4A and 4B). Thus, the enhanced apoptosis in P2neo/neo
compared to WT thymus (Figures 3A and 3B), was closely
associated with an increase in TCRβ/γδ expression. Of
note, MFI of Annexin V+ apoptotic P2neo/neo thymocytes,
was lower compared to the WT (Figure 4D), presumably
due to a lower level of cell surface phosphatidyl-serine in
P2neo/neo cells.
Together, the complementary outcome of these experi-
ments indicates that Runx1 functions in vivo as a negative
regulator of TCR expression. When the temporal expres-
sion of Runx1 is attenuated, levels of TCRβ+/TCRγδ+ thy-
mocytes increase, which may lead to enhanced cell death.
When P1 is turned-on, restoring Runx1 expression in
P2neo/neo cells, apoptosis in mutant thymocytes assumes
normal levels.
Impaired thymocyte differentiation in P2neo/neo embryos
We next employed flow cytometry to study thymocyte dif-
ferentiation in P2neo/neo embryos and neonates. First we
examined the CD4/CD8 double negative (DN) popula-
tion at E15.5 when nearly 100% of thymocytes are DN.
The DN population is divided into four sub-groups, DN1
to DN4, according to the expression of CD25 and CD44
surface markers. Compared to WT, P2neo/neo embryos dis-
played an increase in the proportion of DN3 (CD25+/
CD44-) thymocytes and a corresponding reduction in
DN4 cells (CD25-/CD44-) (Fig. 5A), resulting in a signifi-
cant increase in the ratio DN3/DN4 among P2neo/neo thy-
mocytes (WT DN3/DN4 = 0.65 ± 0.15 and P2neo/neo = 1.51
± 0.31; P < 0.001). To examine P1/P2 usage in the DN
sub-groups we used flow cytometry to sort E15.5 thymo-
cytes based on surface expression of CD25 and CD44 (as
shown in Fig. 5A), and levels of P1 and P2 transcripts was
determined. The levels of P1 and P2 expression did not
differ significantly between DN3 and DN4 subgroups and
was similar to the level shown in Fig. 1D.
Next we examined the CD8/CD4 double positive popula-
tion. At E16.5, P2neo/neo embryos displayed a 2.5-fold
reduction in the proportion of double positive (DP)
CD4+/CD8+ thymocytes as compared to WT (Fig. 5B). At
E17.5 the decrease in proportion of DP thymocytes in
P2neo/neo embryos was more pronounced and accompa-
nied by a marked increase in an abnormal population of
CD4+/CD8low cells (Fig. 5B). A similar subpopulation of
immature CD4+/CD8low was previously observed in mice
with thymocyte specific targeting of Runx1 [13,28] and in
mice bearing a hypomorphic Cbfβ allele [49]. It was pos-
tulated that this abnormal CD4+/CD8low population rep-
resents immature DP thymocytes in which CD8
expression was diminished and CD4 expression was par-
tially de-repressed [13]. Delayed differentiation of P2neo/
neo thymocytes was still apparent at post-natal day (P) 1.5
(Fig. 5B), but recovery to WT proportions was noted at
P3.5.
Taken together, the change in the proportion of DN3/
DN4 thymocytes at early thymopoiesis, the decrease in
DP CD4/CD8 thymocytes and the increase in the abnor-
mal SP CD4+/CD8low population, indicate that during
embryonal thymopoiesis P2 activity is also required for
regulation of CD4/CD8 expression and thereby for the
proper differentiation of DN and DP thymocytes.
Reduction in committed T-cell precursors (TCPs) in P2neo/
neo fetuses
Runx1 is essential for embryonal hematopoiesis and
Runx1-/- mice lack definitive hematopoiesis as well as
hemapoietic colony forming activity in vitro
[16,17,19,20]. In developing FL, Runx1 is expressed in
HSC and in early progenitors [9,16,17], and in WT FL
both promoters are active (Fig. 6A and [50]. In hemat-
opoietic FL cells of P2neo/neo embryos, P1-transcription
was not affected, as was noted earlier for P2neo/neo thymo-
cytes (Fig. 1G), whereas P2 activity was largely attenuated
(Fig. 6A). To assess hematopoietic activity, individual FLs
from WT and P2neo/neo embryos were isolated and ana-BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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The propensity of P2neo/neo thymocytes to undergo apoptosis is associated with elevated expression of TCRβ and TCRγδ Figure 4
The propensity of P2neo/neo thymocytes to undergo apoptosis is associated with elevated expression of TCRβ 
and TCRγδ. (A and B) Expression of TCRβ and TCRγδ on WT and P2neo/neo embryonal thymocytes. (A) Shown are FACS 
analysis dot plots of E15.5 to E18.5 WT and P2neo/neo thymocytes indicating the percentages of cells in each quadrant. Histo-
grams in (B) show the average ± S.E. of TCRβ/TCRγδ proportions of WT and P2neo/neo thymocytes in at least three experi-
ments at each developmental stage. The difference between WT and P2neo/neo was significant at P < 0.005 (*) and P < 0.05 (#) 
by Student's t test. While at E15.5 to E17.5 the proportion of TCRβ/TCRγδ expressing thymocytes was much higher in P2neo/
neo compared to WT, at E18.5 the distribution of P2neo/neo thymocytes resumed normal pattern. The mean fluorescence inten-
sity (MFI) (B right) of E15.5 and E16.5 TCRβ+ P2neo/neo thymocytes was significantly higher than WT (p < 0.005; by Student's t 
test). (C) Expression of TCRβ/TCRγδ in P2neo/neo thymocytes is transcriptionally upregulated. RT-PCR analysis of RNA derived 
from WT and P2neo/neo E16.5 thymocytes using primers specific for the pre-TCRα and the constant regions of TCRβ and TCRγ 
transcripts. Increased number of PCR cycles shows elevated steady-state levels of mRNAs in P2neo/neo thymocytes compared to 
WT. (D and E) Enhanced apoptosis of P2neo/neo thymocytes is associated with elevated expression of TCRβ/TCRγδ. (D) Histo-
grams demonstrating the proportion of apoptotic cells among TCRβ+ or TCRgδ+ thymocytes. TCRβ/TCRγδ positive WT thy-
mocytes (blue) are divided into two main populations, apoptotic (M1) and non-apoptotic, according to level of Annexin V 
(except for E15.5 TCRγδ+ where all cells are apoptotic). Most of TCRβ/TCRγδ positive P2neo/neo thymocytes (red), are at the 
M1 (Annexin Vhigh) apoptotic subset. (E) Proportion of apoptotic thymocytes among TCRβ/TCRγδ positive E15.5, E16.5 and 
E18.5 thymocytes. Bars represent the average ± S.E. of at least three independent experiments for each time point using differ-
ent mice. The differences between WT and P2neo/neo in number of TCRβ+ apoptotic thymocytes were significant at P < 0.01 (*) 
by Student's t test.BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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lyzed for in vitro colony formation. As shown in Fig. 6B,
the number of colonies grown in P2neo/neo cultures was
significantly lower compared to WT. However, because
the size of the colonies in P2neo/neo and WT cultures was
similar (data not shown), the results indicate that P2neo/
neo FL cells contained fewer progenitors compared to WT.
This conclusion was supported by the finding that E17.5
and E18.5 P2neo/neo embryos showed marked reduction
(~50 ± 3%) in the proportion of Gr-1+/CD18+  and
CD11a+/CD11b+ cells compared to WT littermates (Fig.
6C and data not shown).
We next assessed the effect of the P2neo/neo hypomorph on
the development of FL HPC. Runx1 expressing FL HPC
also express CD34, c-Kit and CD44 [16,17]. In E17.5 and
E18.5 P2neo/neo embryos, a 2-fold reduction in the propor-
tion of CD44+/c-Kit+ HPC compared to WT littermates
was observed (Fig. 6C), and even greater reduction was
observed in CD34 positive cells at E14.5–E18.5 (Fig. 6D
and data not shown). FL HPC that are B220low/c-kit+/
CD19- represent an HPC population restricted to the T-
cell and natural killer cell lineages [51]. These FL progen-
itors, termed T-cell precursors (TCPs), are thought to rep-
resent the immediate developmental step before thymic
immigration. Because the hypocellularity of P2neo/neo thy-
mus was noted at the earliest developmental stages (Figs.
1H and 2B), the proportion of TCPs in WT and P2neo/neo
was compared. FACS analysis of B220low/c-kit+/CD19-
E15.5 FL cells, revealed a fourfold reduction in the propor-
tion of P2neo/neo TCPs compared to WT (Fig. 6E). These
results indicated that the proportion of Runx1 expressing
FL HPC, particularly the TCP subset, was markedly
reduced in P2neo/neo compared to WT. This conclusion was
supported by in vitro FTOC progenitor assay, which mon-
itors the capacity of FL TCPs to reconstitute thymic lobes
[51-54] (Fig. 6F). When E15.5 WT and P2neo/neo FL cells
were cultured under limiting dilution conditions in
FTOCs, the frequency of successfully populated thymic
lobes was lower for P2neo/neo TCPs as compared to WT (~1
in 47 P2neo/neo cells vs. 1 in 28 WT cells) (Fig. 6F).
Additionally, when day 16 FTOCs cells were obtained and
CD4/CD8 positive cells analyzed by FACS, an abnormal
differentiation of P2neo/neo thymocytes was observed with
increased proportion of the abnormal population DP
CD4+/CD8low and a twofold reduction in the proportion
of SP CD4+ or CD8+ compared to WT (not shown). This
FTOC result corresponds well with the in vivo delayed
maturation of P2neo/neo fetal thymocytes described in Fig.
5. Collectively, these data indicate that in P2neo/neo
embryos the development of FL HPC of different lineages
was impaired.
P2-mediated expression of Runx1 is required for embryonal thymopoiesis Figure 5
P2-mediated expression of Runx1 is required for embryonal thymopoiesis. (A) Distribution of CD44/CD25 express-
ing thymocytes of E15.5 WT and P2neo/neo embryos. Representative data of five different experiments are shown as FACS dot 
plots; percentages of cells in each quadrant are indicated. (B) Distribution of embryonic and neonatal CD4/CD8 thymocytes. 
WT and P2neo/neo thymocytes of E16.5 and E17.5 embryos and day 1.5 and 3.5 neonates were analyzed. Representative data of 
five different experiments are shown as FACS dot plots; percentages of cells in each quadrant are indicated.BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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P2-mediated embryonal expression of Runx1 is required for development of FL HPC Figure 6
P2-mediated embryonal expression of Runx1 is required for development of FL HPC. (A) RT-PCR analysis of RNA 
from E13.5 FL cells of WT and P2neo/neo embryos. P2-mediated transcription in P2neo/neo was largely attenuated, whereas P1-
mediated transcription was apparently unaffected. (B) Colony forming activity of FL hematopoietic stem/progenitor cells. Col-
onies (>30 cells in size) were scored on day 7 of incubation. Shown are average numbers of colonies per FL ± S.E. of at least 
three different WT or P2neo/neo embryos at E12.5 and E13.5. The difference between WT and P2neo/neo colony number is signif-
icant (*) at P < 0.001 by Student's t test. (C and D) Altered expression of surface antigens on P2neo/neo FL HPC. (C) Expression 
profiles of Gr-1, CD18, CD11b, CD11a, CD44 and c-Kit, in FL HPC from E17.5 WT and P2neo/neo embryos. Representative 
data of at least three different experiments are shown as FACS dot plots; percentages of cells in each quadrant are indicated. 
Note the 2-fold decrease in the proportions of Gr-1+/CD18+ and CD11a+/CD11b+ (left panels) as well as CD44+/c-Kit+ (right 
panel), FL cells in P2neo/neo compared to WT. (D) Proportion of CD34+ FL HPC. Profiles of WT and P2neo/neo FL HPC, filled 
(blue) and unfilled (red) histograms, respectively, at E14.5, E16.5 and E18.5. Shown are representative results of at least three 
different experiments. Numbers at the upper right corners are percentages of CD34+ cells in WT (upper) and P2neo/neo 
(lower). Note the marked decrease in the proportions of P2neo/neo CD34+ HPC. (E) Analysis of committed FL T-cell precursors 
(TCPs). FACS analysis showing the distribution of B220+/c-Kit+/CD19- FL HPC of E15.5 WT and P2neo/neo embryos. Gated 
CD19- precursors (R1) were analyzed for c-Kit and B220 expression. Note the 4-fold decrease in the proportions of c-Kit+/
B220low/D19- TCPs (R2) in P2neo/neo FL HPC. Data shown on the right are average ± S.E. of four independent experiments using 
four different mice. The difference between the percentages of TCPs from WT and P2neo/neo FL HPC is significant at P < 0.005 
by Student's t test. (F) Reduced capacity of P2neo/neo FL HPC to colonize FTOC. Isolated E15.5 FL HPC from WT or P2neo/neo 
embryos were set to differentiate, under limiting dilution conditions, for 16 days in E14.5 WT FTOC. Shown are percentage of 
unsuccessfully populated lobes per cultured cells and the calculated frequencies of three different independent experiments.BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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Runx1 P2neo allele failed to rescue the embryonal lethality 
phenotype of Runx1-/- mice
Homozygous disruption of Runx1 results in a complete
absence of FL hematopoiesis and the mice die between
E11.5 and E12.5 of hemorrhages in the central nervous
system [19,20]. P2neo/neo mice were born and showed no
sign of hemorrhages, indicating that expression levels of
Runx1 in homozygous P2neo/neo during early embryogene-
sis were sufficient to rescue the Runx1-/- phenotype. This
occurrence raised the question of whether Runx1 levels
provided by activity of a single P1 will also be sufficient to
rescue the null phenotype. To address this issue we gener-
ated a compound mutant strain Runx1lz; Runx1P2neo by
mating Runx1lz/+ mice [16] with Runx1P2neo/+. These mice
had one null allele expressing a fused Runx1-LacZ protein
and one P2neo allele expressing WT P1 (Fig. 7A). Com-
pound mutant Runx1lz;Runx1P2neo embryos died between
E11.5 and E12.5 and suffered from hemorrhages in the
nervous system (Fig. 7B). The most extensive bleedings
was seen in the 4th ventricle, the ventral metencephalon
and spinal cord. Moreover, the liver of E12.5 compound
mutant embryos was depleted of hematopoietic cells (Fig.
7C), indicating lack of definitive hematopoiesis, similar
to the previously reported Runx1-/- phenotype [16,19,20].
These results indicated, that during midgestation, angio-
genesis and definitive hematopoiesis are highly sensitive
to the dosage of Runx1 as activity of a single P1 was not
sufficient to rescue the Runx1-/- phenotype. This conclu-
sion is consistent with the previously reported data which
was based on transplantation assays [17,18,55]. This
observation may also pertain to the unique role of P2
activity during midgestation angiogenesis and/or early
hematopoiesis.
Early lethality phenotype of P2neo/neo neonates is rescued 
by excision of the neo cassette in early T cell progenitors
As noted earlier, P2neo/neo neonates die within a few days
after birth. The reasons for this early lethality are not clear.
While P2-mediated expression diminished in several
P2neo/neo tissues, including stomach, intestine and kidney
(Fig. 1), the most striking abnormalities were noted in
thymic development and thymopoiesis. We thus
addressed whether these abnormalities could be rescued
by specific removal of the neo cassette in early thymopoi-
esis and whether this occurrence will extend the life span
of P2neo/neo neonates.  Runx1-P2neo/neo mice were mated
with a Lck-cre transgenic line [56] to excise the neo and
regain P2 activity in thymocytes (Fig. 8A). Contrary to
P2neo/neo mice, the P2/Lck-Cre mice developed normally
and outwardly were indistinguishable from WT litterma-
tes. Nevertheless, embryonal thymopoiesis of P2/Lck-Cre
was not completely normal and embryos exhibited a
lower number of Runx1 expressing thymocytes (Figs. 8B
and 8C). This may be due to an incomplete excision of the
neo cassette in all T cell progenitors. Significantly, how-
ever, Runx1 expression level in P2/Lck-Cre was sufficient
to allow for normal thymic development. Of note, P2-
mediated Runx1 expression in other Runx1 expressing
cells, such as epithelial cells, was not rescued in P2/Lck-
Cre mice (Fig. 8D and data not shown).
Discussion
Runx1 is an important cell-linage specific regulator of
definitive hematopoiesis and thymopoiesis. The unique
spatio/temporal expression pattern of Runx1 is attained
through alternative usage of its two promoters, P1 and P2
[29,30,57] that also impacts on translation efficacy and
repertoire of protein isoforms [30,57]. While it was clear
Runx1 P2neo allele failed to rescue the embryonal lethality  phenotype of Runx1-/- mice Figure 7
Runx1 P2neo allele failed to rescue the embryonal 
lethality phenotype of Runx1-/- mice. (A) Schematic rep-
resentation of Runx1 locus in the two Runx1 mutant strains 
used to generate the compound mutant strain 
Runx1lz;Runx1P2neo. (B) Runx1lz;Runx1P2neo die at E11.5 to 
E12.5 due to hemorrhages in the CNS and/or lack of FL 
hematopoiesis. Left: Lateral view of a whole mount com-
pound Runx1lz;Runx1P2neo E11.5 embryo stained for β-galac-
tosidase activity. Hemorrhages are seen in the 4th ventricle, 
the ventral metencephalon and spinal cord. Right: Hematoxy-
lin and eosin (H&E) staining of a section through the spinal 
cord exhibits focal hemorrhage (arrow head). (C) H&E stain-
ing of WT (left view) and Runx1lz;Runx1P2neo (right view) 
E12.5 fetal liver. Note the absence of definitive hematopoi-
etic precursors (deep purple cells) in Runx1lz;Runx1P2neo FL as 
compared to WT. The data demonstrate that activity of a 
single Runx1 P1 was not sufficient to rescue the embryonal 
lethal phenotype of Runx1-/- mice.BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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that transcriptional regulation of Runx1 expression is an
important element of its biological function, little was
known about the role of the two promoters during devel-
opment, and about how and when they are differentially
regulated. Is the alternative promoter usage of human and
mouse RUNX1/Runx1 a reflection of vertebrates' higher
complexity? Differential usage of alternative promoters
enables diversified transcriptional regulation within a sin-
gle locus and may thus serve as a molecular basis for the
higher complexity of certain vertebrates' systems, such as
the immune system. Indeed, while the RUNX genes are
highly conserved throughout the animal kingdom, more
primitive animals such as the nematode C. elegance and
the sea urchin contain only one gene regulated by a single
promoter [3,8]. This single promoter is the equivalent of
vertebrates' P2.
Differential P1/P2 usage during embryogenesis
The use of hypomorphic alleles for studying essential
genes at the organismal level is a well-established
approach. We employed mice homozygous for a hypo-
morphic Runx1 allele, which caused a profound attenua-
tion of P2 activity, to investigate the biological role of P2
during embryogenesis. Specifically, we analyzed the
Rescue of P2neo/neo dependent thymic defect by T-cell specific removal of the neo cassette Figure 8
Rescue of P2neo/neo dependent thymic defect by T-cell specific removal of the neo cassette. (A) Specific excision of 
the neo cassette in P2/Lck-Cre mice. Southern blot analysis using a probe spanning the region indicated by the red bar assessed 
the level of neo excision in thymocytes, stomach epithelium and splenocytes of 4 week-old P2/Lck-Cre mice. The positions of 
XbaI cleavage sites are shown (X). The probe hybridized to a 3.4 Kb- and a 5.4 Kb XbaI genomic fragments derived from WT 
and P2neo/neo allele, respectively. Insertion/excision of the neo cassette by Lck-Cre eliminated the middle XbaI site (shown in 
WT as bold blue) generating the 4.6 Kb fragment derived from the P2/Lck-Cre allele. (B) Regeneration of thymus cellularity in 
P2/Lck-Cre mice. At day-1.5 the number of thymocytes in P2/Lck-Cre thymic lobes was near normal compared to WT litter-
mates. Data shown are average ± S.E. of five independent experiments using five mice of each genotype (WT, P2neo/neo and P2/
Lck-Cre). The difference between WT and P2neo/neo is significant at P < 0.001 by Student's t test. (C) Recovery of thymopoiesis 
and thymic organogenesis in P2/Lck-Cre embryos. Histological analysis and Runx1 expression in thymic lobes derived from 
E15.5 and E16.5 WT, P2neo/neo and P2/Lck-Cre embryos. Shown are H&E stained transverse sections immunostained for Runx1. 
(D) Runx1 expression was not rescued in P2/Lck-Cre epithelial cells. IHC analysis of Runx1 expression in esophagi derived 
from E16.5 WT, P2neo/neo and P2/Lck-Cre embryos. Transverse sections showing Runx1 expression in epithelial cells lining the 
lumen of WT (arrow), but not of P2neo/neo or P2/Lck-Cre esophagus. Several other tissues including stomach and nasal cavity 
were similarly analyzed and revealed no expression of Runx1 in epithelia of P2neo/neo or P2/Lck-Cre mice (not shown).BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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impact of the resulting hypomorphic Runx1 expression
on FL HPC development and early thymopoiesis. We
found that during embryogenesis Runx1 is developmen-
tally regulated through alternative usage of P1 and P2. In
certain tissues, including kidney, tongue and liver both P1
and P2 are active, whereas in others such as intestinal epi-
thelium and early thymocytes P2 activity predominates.
Contrary to Runx1 null mice, in which embryonic
lethality occurs at ~E12.5 [19,20], P2neo/neo mice develop
to term, implying that during early development the activ-
ity of P1 prevails. This conclusion is supported by the
finding that both P1- and P2-transcripts are found in FL of
E12.5 embryos [50]. The notion that both P1 and P2 are
active during early hematopoiesis correlates well with the
finding that P2neo/neo embryos displayed moderate and
severe hematopoietic defects in the liver and thymus,
respectively.
P2 activity is essential for embryonal thymopoiesis and 
thymus development
Thymic development in the mouse begins at ~E9.5 [42].
Runx1 is highly expressed in thymocytes, but not in thy-
mus epithelium [9,13,14]. Using in-situ hybridization, RT-
PCR and IHC we demonstrate that during early thy-
mopoiesis activity of P2 predominates. The P1 is upregu-
lated at E17.5 and its activity persists thereafter, while the
activity of P2 declines after birth. At E11 the thymic rudi-
ment is colonized by the first wave of committed T-cell
precursors (TCP) [54] which endure in the thymus until
E17 [58]. It is tempting to speculate that P2 activity is con-
fined to descendants of the first wave TCP, whereas P1 is
active in thymocytes originating in the second wave. Con-
sistent with this hypothesis, the first wave P2neo/neo thy-
mocytes contained a markedly reduced level of Runx1
compared to WT, whereas in second wave thymocytes the
level was similar to WT due to switch-on of P1 at E17.5.
These second wave thymocytes grow exponentially after
birth, when P1 is more active, and become the major cell
population in the thymus.
During early stages of thymus development (i.e. E14.4 to
E16.5) a marked reduction in thymic cellularity was
observed in P2neo/neo embryos. We show that this occur-
rence was due to enhanced apoptosis of P2neo/neo thymo-
cytes. But why were E14.4 to E16.5 P2neo/neo thymocytes
more susceptible to apoptosis than WT cells?
Selection processes in the thymus ensure that peripheral T
cells are responsive to foreign antigens but tolerant to self-
antigens. This occurs through positive and negative β-
selections. Thymocytes, whose TCR engaged peptide/
MHC molecules productively, escape their inherent pro-
grammed cell death and subsequently are induced to pro-
liferate. On the other hand, thymocytes that react strongly
with self-peptide-MHC molecules are actively eliminated
[59-61]. According to the avidity model, selection occurs
only when signals received through the TCR fall between
two thresholds: signals below the one are incompatible
with survival (death by neglect), while signals above the
other result in deletion [47,62,63]. We hypothesize that
the elevated TCR levels in P2neo/neo thymocytes disturbed
this delicate balance and disposed a larger proportion of
P2neo/neo T cells to apoptosis.
Several studies in transfected cells have demonstrated the
involvement of Runx1 in transcription regulation of TCRs
expression [8]. Specifically, we have shown that Runx1
can act as a transcriptional repressor in TCR regulation [4].
Thus, it is conceivable that the increased levels of TCRs in
embryonic P2neo/neo thymocytes resulted from the reduced
Runx1 expression in these cells, and that the higher TCRs
levels lead to a higher avidity of TCR-MHC interactions,
which programmed the cells to apoptosis. This hypothesis
is supported by Runx1F/F/Lck-Cre mice, which show
enhanced negative selection of Runx1-/- thymocyte [13],
and by the finding that upon recovery of Runx1 expres-
sion in P2neo/neo thymocytes, TCR expression and apopto-
sis resumed WT levels. Potentially related, mice
homozygous for a knock-in Runx1 cDNA that are lacking
the C-terminal VWRPY, exhibit thymic hypocellularity
[28]. The VWRPY motif, which is highly conserved among
all RUNX proteins, is essential for recruitment of the tran-
scriptional co-repressor Gro/TLE [4,7,64] and subsequent
repression of target genes [4,7]. Thymic hypocellularity
was also noted in mice bearing a hypomorphic allele of
Cbfβ, the non-DNA binding partner of Runx1, which is
essential for the function of RUNX proteins [49].
In addition to the marked hypocellularity, thymi of P2neo/
neo embryos contained an increased proportion of DN3
(CD25+/CD44-) thymocytes, a reduced proportion of DP
CD4+/CD8+ thymocytes and a pronounced increase in an
abnormal population of immature CD4+/CD8low cells.
The increase in DN3 and CD4+/CD8low thymocyte popu-
lations was previously observed in adult Runx1F/F/Lck-Cre
mice due to diminished Runx1 in DN thymocytes and the
consequent derepression of CD4  [13]. More recently a
similar increase in CD4+/CD8low  thymocytes was also
observed in fetuses of Cbfβrss/- mice bearing the hypomor-
phic Cbfβ allele [49], indicating that Cbfβ is required for
CD4 silencing by Runx1. Abnormally high proportion of
CD4+ thymocytes was also noted in embryos of the Runx1
knock-in mutant lacking the VWRPY motif [28]. This find-
ing suggests that Runx1-mediated repression of CD4 in
DN thymocytes involves the recruitment of Gro/TLE, as in
case of Runx3-mediated silencing of CD4 in DP thymo-
cytes [7].BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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Attenuation of P2 activity affects development of FL HPC
Runx1 is essential for the emergence of embryonal HSC
[16-18]. Analysis of FL hematopoiesis in P2neo/neo
embryos revealed that the emergence and commitment of
HPC to either myeloid or lymphoid lineages was not
affected by attenuation of P2. However, the noted delay in
differentiation and expansion of various P2neo/neo progen-
itor populations indicated that development of FL HPC
was sensitive to diminution in P2 activity. Interestingly,
the overall phenotype of FL HPC in P2neo/neo embryos
resembled the phenotype observed by Cai et al [18] in het-
erozygous Runx1+/-  fetuses, suggesting a gene dosage
effect. In developing FL activity of P1 emerged early and
persisted throughout gestation [50]. As P1 activity was
largely unaffected in P2neo/neo HPC, it is conceivable that
the hypomorphic expression in P2neo/neo FL creates condi-
tions resembling haploinsufficiency [18], in line with the
large body of literature documenting hematopoietic
defects due to hemizygous dosage of Runx1 [2,17,20,65].
However, it is worth noting that the effect of P2neo/neo
hypomorph is not merely through gene dosage, because
contrary to Runx1+/- the P2neo/neo neonates die within a
few days after birth.
Rescue of the early lethality of P2neo/neo neonates
Despite the diminished P2-activity and reduced Runx1
dosage, P2neo/neo embryos developed to term. Thus the
residual P2 activity plus the apparent WT expression of P1
were sufficient to support normal development of P2neo/
neo embryos through gestation. However, inactivation in
P2neo/neo embryos of one P1 allele, as in the compound
mutant Runx1lz;Runx1P2neo, which further reduced Runx1
dosage, caused hemorrhages in the nervous system and
mid-gestation (E11.5–E12.5) lethality. This result defined
the threshold level requirement of Runx1 for rescue of the
nervous system hemorrhages. While P2neo/neo embryos
developed to term, neonates die within a few days after
birth. Specific removal of the floxed P2-neo cassette by
crossing P2neo/+ mice with Lck-Cre transgenics resumed P2
expression in early thymopoiesis, allowed for normal
thymic development and rescued the neonatal lethality.
Of note, the neonatal lethality was rescued even though
expression of P2 in the gastrointestinal tract of P2neo/neo/
Lck-Cre mice was not resumed. This occurrence indicated
that lethality of P2neo/neo neonates was not due to lack of
Runx1 expression in gastrointestinal tract epithelium,
despite the striking reduction of nutrients in the gastroin-
testinal tract of P2neo/neo neonates (see Additional File 2C
and 2E). As athymic nude mice live through adulthood, it
is conceivable that impaired thymopoiesis in P2neo/neo
embryos, especially at the negative selection step, resulted
in emergence of pathogenic T cells that cause the neonatal
lethality. Finally, as the N-terminus of Runx1 proteins
encoded by P2-mRNA differs from that of P1 [3], it is
tempting to speculate that the hematopoietic phenotypes
of P2neo/neo embryos were caused not only by gene dosage,
but are due to the lack of P2 isoforms. Elucidating the spe-
cific role of the P1- and P2-protein isoforms in Runx1
biology, particularly early thymopoiesis, awaits further
investigations.
Conclusion
Differential usage of alternative promoters enables diver-
sification of transcriptional regulation within a single
locus and thereby plays a significant role in the control of
gene expression. During mouse embryogenesis the spatio/
temporal expression of Runx1 is developmentally regu-
lated by alternative usage of two mutually distinct pro-
moters, P1 and P2. These promoters are not only
differentially regulated, but also give rise to mRNAs with
variant 5'-UTRs and to structurally different protein iso-
forms. Our studies support a model whereby attenuation
of P2 affects mRNA levels and protein isoforms repertoire
within the cell and thereby creates the hematopoietic phe-
notype of P2neo/neo embryos. The findings provide in vivo
evidence for the non-redundant function of P1 and P2
and underscore the significance of alternative promoter
usage in Runx1 biology.
Methods
Generation of Runx1 P2neo/neo mice
Runx1 genomic clone was isolated from 129/Sv-derived
ES cells DNA and a 7.2 Kb EcoRI-PstI fragment spanning 3
Kb upstream of P2, exon 2 and 2.4 Kb of intron 2 [57] was
subcloned into pBluescript. A 2 Kb pgk-neo cassette was
inserted into the XbaI site at nucleotide 27675861 of the
mouse genome (accession # NT-039625). R1 ES cells were
transfected with the targeting construct and homologous
recombinants were evaluated by Southern blot analysis.
Targeted ES cells were used to create several chimeras that
passed the mutated Runx1 allele to their progeny. Two
independent P2neo/neo mouse lines from two different ES
clones were established and bred onto ICR and MF1
strains. As identical phenotypes were observed with
mutant mice generated from either of the two-targeted ES
cell lines, and with mutant mice bred on either ICR or
MF1 background, in most cases we have combined the
data. Genotypes were examined by PCR using genomic
tail DNA and when applicable verified by Southern anal-
ysis. The noon of vaginal plug was considered E0.5. To
remove the neo cassette, homozygotes P2neo/neo mice were
crossed onto the transgenic Cre-deleter mouse strain PGK-
Cre [40] generating mice lacking the neo  cassette. Cre-
mediated excision of neo was confirmed by PCR. Mice
were bred and maintained in a pathogen-free facility. All
experiments involving mice were approved by the Institu-
tional Animal Care and Use Committee (IACUC) of the
Weizmann Institute.BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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Isolation of hematopoietic cells
Thymic lobes and livers of embryos or newborns were
aseptically removed, and a single-cell suspension was gen-
erated. When required, red blood cells were lyzed with 1:9
volumes of PBS:RCLB (0.9% NH4Cl, 0.1% KHCO3,
0.0037% EDTA, pH7.2).
Protein and RNA analysis
Tissues were collected, washed once in PBS, and proteins
or RNA were extracted. Protein extracts were subjected to
Western blot analysis as described previously [30,35].
Poly(A)+ RNA was purified from 150 mg of total RNA
using oligo(DT) magnetic beads (Dynal. Oslo, Norway)
and subjected to Northern blot analysis as previously
described [30,31]. WT thymocytes expressed four alterna-
tively spliced isoforms of Runx1 transcripts, of which the
2 Kb- and 6 Kb result from P1-mediated transcription,
while the 4 Kb- and 8 Kb from P2 activity [31].
RNA preparation and RT-PCR analysis
Total RNA isolated using Tri-Reagent™ (MRC) was reverse
transcribed using SuperScript™ II reverse transcriptase
(Invitrogen) and resulting cDNA was subjected to PCR
reactions using the SuperTherm polymerase (Hoffman-
La-Roche). To amplify Runx1 specific sequences, we used
a common antisense primer that hybridizes to a sequence
in the Runt domain exon 4 with two different sense prim-
ers that were complementary to either P1- or P2 5'UTR.
Thereby the expression of both P1 and P2 regions were
simultaneously monitored, providing a reliable readout
of their relative expression levels. The sequences of prim-
ers and conditions used for PCR analysis of Runx1 and
TCR are as follows: Primers for Runx1 amplification: 5'-
GAAACGATGGCTTCAGACAGC-3' (P1-sense), 5'-CTT-
GGGTGTGAGGCCGATCC-3' (P2-sense), and 5'-
ATGACGGTGACCAGAGTGCC-3' (runt domain anti-
sense).  β-actin was used as an internal reference, with
primers: 5'-GATGACGATATCGCTGCGCTG-3' (sense)
and 5'-GTACGACCAGAGGCATACAGG-3' (antisense).
The PCR conditions used were as follow: 94°C for 3 min,
followed by 40 cycles of 94°C for 45 s, 57°C for 45 s and
72°C for 45 s. Primers for TCRs amplification: 5'-TCCTC-
CCCCAACAGGTAGCT-3' (Pre TCRα-sence), 5'-
GGCAAACCACCAGCATGTG-3' (Pre TCRα-antisence), 5'-
TCTCATAGAGGATGGTGGTGGCAGACA-3' (constant
TCRb-sence), 5'-CTGCTACCTTCTGGCACAATCC-3' (con-
stant TCRβ-antisence), 5'-AGGCTTGATGCAGACATTTC-
CCCC-3' (constant TCRγ-sence) and 5'-
CTTGCCAGCAAGTTGTAGGCTTGG-3' (constant TCRγ-
antisence). The PCR conditions were as follow: 94°C for
3 min, followed by increasing number of cycles (25, 30,
35) of 94°C for 45 s, annealing for 45 s and 72°C for 60
s. Annealing temperatures were the following: 56°C-
TCRα, 55°C-TCRβ and 59°C-TCRγ. All PCR products
were analyzed by 1.5% agarose gel and visualized by
staining with ethidium bromide.
In-Situ hybridization
In situ hybridization with Digoxigenin (DIG)-labeled
antisense and sense Riboprobes made of the P2-5'UTR,
spanning nucleotide No. 27,373,200-27,374,550 in Gen-
bank Accession # Mm16_39665_36 (see S1A), was per-
formed according to published procedures [66], using 14
μ frozen sections. DIG labeled Riboprobes were detected
by anti-DIG antibody conjugated to alkaline phosphatase
(Roche), and developed with nitro blue tetrazolium/5-
bromo-4-chloro-3-indole-phosphate.
Histology and immunohistochemistry
Histology and immunohistochemistry were performed as
previously described [9,10]. Polyclonal anti Runx1 anti-
bodies (1:1000) [9,35], and anti Ki-67 antibodies (1:50)
(DakoCytomaion), were incubated overnight at room
temperature in blocking solution of PBS containing 0.5%
Triton X-100 and 3% heat inactivated normal goat serum
for anti Runx1, or normal rabbit serum for anti Ki-67 [67].
Bound antibody was detected using biotinylated goat
anti-rabbit IgG secondary antibodies for Runx1, and goat
anti-rat IgG for Ki-67. The ABC complex from Vectastain
kit (Vector Laboratories, Burlingame, CA) was used for
peroxidase detection. Slides were counterstained with
hematoxylin.
Flow cytometric analysis
Flow cytometry was performed as previously described
[14,68], using the following mAbs from Pharmingen (San
Diego, CA): CD4-FITC, CD8-PE, CD44-FITC, CD25-PE,
TCRβ-FITC, TCRβ-biotinylated, TCRγδ-PE, c-KIT-PE,
CD19-FITC, B220-biotinylated, Gr-1-FITC, CD18-PE,
CD11a(LFA-1)-FITC, CD11b(Mac-1)-PE, CD34-FITC,
streptavidin-APC.
Proliferation assay and apoptosis analysis
Proliferation assay was conducted as before [14]. 103
FACS sorted Annexin V negative cells were assayed for pro-
liferation using [3H]thymidine (specific activity 25 Ci/
mmole). Apoptosis was monitored by double staining
with Annexin V and PI. Annexin V-FITC-conjugated anti-
coagulant (Annexin-V-Fluos Roche, Mannhein, Germany)
was used according to manufacturer's instructions. In situ
apoptotic cells were detected by staining paraffin sections
of thymic lobes with ApopTag Apoptosis Detection Sys-
tem (Biotech). Activated caspase-3, a key apoptotic
marker, was detected by IHC of paraffin sections with pol-
yclonal antibodies against activated caspase-3 (Cell Sign-
aling Technology).BMC Developmental Biology 2007, 7:84 http://www.biomedcentral.com/1471-213X/7/84
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Fetal thymic Organ Culture (FTOC)
Isolation of WT E14.5 thymic lobes, treatment with 1.35
mM 2'-deoxyguanosine (2-dG) (Sigma, St Louis, MO) and
incubation of lobes with WT or P2neo/neo FL HPC by means
of the hanging drop procedure, were performed as previ-
ously described [69]. After 16 days in organ culture, the
lobes were removed, rinsed in medium and analyzed for
newly populated thymocytes. Limiting dilution assay was
performed as described by Jenkinson et al [52] and Dou-
gai et al [51,54]. The frequency of TCPs per thymic lobe
was deduced based on the Poisson probability distribu-
tion as previously described [51,54].
Colony forming unit (CFU) assay
105 FL cells were cultured in 1 ml of single layer DMEM
culture medium containing 0.33% agar and 20% horse
serum supplemented with 50 ng/ml stem cell factor, 20
ng/ml IL-3, 25 ng/ml IL-6, 5 ng/ml GM-CSF, and 2 ng/ml
G-CSF to provide optimal conditions for multiplication
and differentiation of multipotential hematopoietic pro-
genitors of definitive hematopoiesis [19]. The number of
colonies was determined after 7 days of incubation.
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